Identification of a New Series of Flavopiridol-like Structures As Kinase Inhibitors with High Cytotoxic Potency
Overview
Authors
Affiliations
In this work, unique flavopiridol analogs bearing thiosugars, amino acids and heterocyclic moieties tethered to the flavopiridol via thioether and amine bonds mainly on its C ring have been prepared. The analogs bearing thioether-benzimidazoles as substituents have demonstrated high cytotoxic activity in vitro against up to seven cancer cell lines. Their cytotoxic effects are comparable to those of flavopiridol. The most active compound 13c resulting from a structure-activity relationship (SAR) study and in silico docking showed the best antiproliferative activity and was more efficient than the reference compound. In addition, compound 13c showed significant nanomolar inhibition against CDK9, CDK10, and GSK3β protein kinases.
Flavopiridol: a promising cyclin-dependent kinase inhibitor in cancer treatment.
Baghel U, Kriplani P, Patel N, Kaur M, Sharma K, Meghani M Naunyn Schmiedebergs Arch Pharmacol. 2024; .
PMID: 39589530 DOI: 10.1007/s00210-024-03599-2.
Unlocking the Pharmacological Potential of Benzimidazole Derivatives: A Pathway to Drug Development.
Monga J, Ghosh N, Rani I, Singh R, Deswal G, Dhingra A Curr Top Med Chem. 2024; 24(5):437-485.
PMID: 38311918 DOI: 10.2174/0115680266283641240109080047.
The Pharmacological Implications of Flavopiridol: An Updated Overview.
Joshi H, Tuli H, Ranjan A, Chauhan A, Haque S, Ramniwas S Molecules. 2023; 28(22).
PMID: 38005250 PMC: 10673037. DOI: 10.3390/molecules28227530.
CDK9 inhibitors in cancer research.
Huang Z, Wang T, Wang C, Fan Y RSC Med Chem. 2022; 13(6):688-710.
PMID: 35814933 PMC: 9215160. DOI: 10.1039/d2md00040g.
Chiral Flavonoids as Antitumor Agents.
Pinto C, Cidade H, Pinto M, Tiritan M Pharmaceuticals (Basel). 2021; 14(12).
PMID: 34959668 PMC: 8704364. DOI: 10.3390/ph14121267.